Safety and pharmacokinetics of the oral iron chelator SP‐420 in β‐thalassemia. Issue 12 (31st October 2017)

• Record Type: Journal Article
• Authors: Taher, Ali T.; Saliba, Antoine N.; Kuo, Kevin H.; Giardina, Patricia J.; Cohen, Alan R.; Neufeld, Ellis J.; Aydinok, Yesim; Kwiatkowski, Janet L.; Jeglinski, Brenda I.; Pietropaolo, Keith; Berk, Gregory; Viprakasit, Vip
• Is Part Of: American journal of hematology. Volume 92:Issue 12(2017:Dec.)
• Page Start: 1356
• Page End: 1361
• Publication Date: 2017-10-31
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.24914
• Languages: English
• ISSNs: 0361-8609

Abstract

Abstact: Our phase I, open‐label, multi‐center, dose‐escalation study evaluated the pharmacokinetics (PK) of SP‐420, a tridentate oral iron chelating agent of the desferrithiocin class, in patients with transfusion dependent β‐thalassemia. SP‐420 was administered as a single dose of 1.5 ( n = 3), 3 ( n = 3), 6 ( n = 3), 12 ( n = 3), and 24 ( n = 6) mg/kg or as a twice‐daily dose of 9 mg/kg ( n = 6) over 14‐28 days. There was a near dose‐linear increase in the mean plasma SP‐420 concentrations and in the mean values for C max and AUC0‐τ over the dose range evaluated. The median t max ranged from 0.5 to 2.25 h and was not dose dependent. The study was prematurely terminated by the sponsor due to renal adverse events (AE) including proteinuria, increase in serum creatinine, and one case of Fanconi syndrome. Other adverse effects included hypersensitivity reactions and gastrointestinal disturbances. Based on current dose administration, the renal AE observed outweighed the possible benefits from chelation therapy. However, additional studies assessing efficacy and safety of lower doses or less frequent dosing of SP‐420 over longer durations with close monitoring would be necessary to better explain the findings of our study and characterize the safety of the study drug.